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Summary Cell proliferation of transitional cell bladder cancer (TCC) was determined by PCNA (proliferating
cell nuclear antigen)/cyclin immunostaining in 178 TCCs and the results were related to established prognostic
factors, progression and survival during a mean follow-up period of 10 years. The fraction of PCNA/cyclin
positive nuclei was related to T-category (P= 0.008), papillary status, WHO grade, DNA ploidy, S phase
fraction, M/V index (volume corrected mitotic index) and AgNORs (silver stained nucleolar organiser regions)
(for all P<0.001). TCCs presenting with pelvic lymph node metastasis at diagnosis had a significantly higher
growth fraction than the tumours confined to the bladder wall (P<0.001). The fraction of PCNA/cyclin
positive nuclei predicted progression in T-, N- and M-categories (P<0.001). In Ta-Ti tumours high fraction
of PCNA/cyclin positive nuclei predicted metastasis (P = 0.019). In survival analysis the fraction of PCNA/
cyclin positive nuclei predicted survival in the entire cohort (P< 0.001) and in Ta-TI tumours (P = 0.0005). In
a multivariate survival analysis the fraction of PCNA/cyclin positive nuclei showed independent predictive
value in the entire cohort (P = 0.046), in papillary tumours (P= 0.006) and in Ta-TI tumours (P = 0.015). The
results show that the growth fraction as determined by PCNA/cyclin immunostaining is a significant prognos-
tic variable in TCC.
PCNA/cyclin is an 36 kDa non-histone nuclear polypeptide
and an auxiliary protein to DNA polymerase delta (Bravo et
al., 1987). PCNA/cyclin is also necessary for DNA replica-
tion (Jaskulski et al., 1988) and PCNA/cyclin is the nuclear
antigen that is detected in proliferating cells by auto-
antibodies in patients with systemic lupus erythematosus
(Miyachi et al., 1978). At present commercially available
antibodies can recognise PCNA/cyclin in conventionally fixed
and processed histological material (Kamel et al., 1991;
Woods et al., 1991; Yu et al., 1991; Benjamin et al., 1991).
Immunohistochemical assessment of cell proliferation has
advantages over other techniques such as flow cytometric S
phase fraction (Blomjous et al., 1989; Lipponen et al., 1991c;
Shaaban et al., 1991) since the tissue architecture is intact
and individual proliferating cells can be visualised in their
local context. Until now the best antibody directed against
proliferating cells is Ki-67 (Gerdes et al., 1983; Tsujihashi et
al., 1991) which can only be used in fresh frozen material
limiting the assessment of architectural features. Recent
studies show that PCNA/cyclin immunostaining and Ki-67
immunostaining carry similar information on cell prolifera-
tion (Kamel et al., 1991) and have also prognostic value in
human tumours (Woods et al., 1991; Yu et al., 1991). As far
as the authors are aware PCNA/cyclin has not been pre-
viously studied in TCC. The aim of the present analysis was
to assess the fraction ofproliferating cells in TCC by PCNA/
cyclin immunostaining and correlate the findings to clinical
stage, papillary status, WHO grade, DNA ploidy, S phase
fraction, mitotic frequency, Ag-NORs, progression and sur-
vival in 178 patients followed up for a mean of 10 years in
one Finnish institution.
Materials and methods
The study comprised patients with a newly diagnosed pri-
mary TCC treated at Kuopio University Hospital during the
years 1965-1985. The follow-up analysis was done in Janu-
ary 1990 and the mean (s.e.) observation period is 10.2 (0.3)
years (range 5-25). In total there were 178 patients of ages
26-84 years, [mean(s.e.) 66.8 (1.0) years] and the female/male
ratio was 36/142. Occasional patients were excluded from the
initial cohort (Lipponen et al., 1991b,c,d) because of
insufficient biopsy specimens for immunohistochemistry. The
treatment and follow-up investigators were done according to
standard practice (Zingg & Wallace, 1985) and the treatment
of patients has been detailed previously (Lipponen et al.,
1990b, 1991b). The initial staging of tumours was based on
the results of excretory pyelography, transurethral biopsy,
cytological examination of voided urine and bimanual pal-
pitation under anesthesia. In many of the muscle invasive
tumours during the latest years a computed tomography or
ultrasonography was done. Screening for metastases included
bone and chest radiography, laboratory tests (erythrocyte
sedimentation rate, red and white blood cell counts, serum
calcium, alkaline phosphate, liver function tests), abdominal
ultrasonography, and when appropriate, bone scintigraphy
and lymphography. Tumours, nodes and metastasis classi-
fication was done according to UICC 1978 (UICC, 1978) and
it was based on the above mentioned examinations added
with the pathologists reports. The follow-up investigations
were done at 3 month intervals during the first 2 years and
thereafter at 6 months intervals. If a recurrent growth was
observed the follow-up program was started again. The treat-
ment of recurrent tumours was based on the same principle
as the treatment of primary tumours. Many of the patients
who died were autopsied to ascertain the extent and metas-
tasis of tumours at the time of death.
Histological methods
The histological samples were preoperative biopsy specimens.
The samples were fixed in buffered formalin (pH 7.0), embed-
ded in paraffin, sectioned at 5 gm and stained with hematox-
ylin and eosin or Van Gieson stains for grading. The samples
were graded according to WHO (Mostofi, 1973). The distri-
bution of cases into WHO grades and T-categories is shown
in Table I. The papillary status of tumours was recorded and
the tumours were divided into papillary (n = 149) and
nodular (n = 29) types.
Immunohistochemistry
For immunohistochemical demonstration of PCNA/cyclin,
5 flm sections from the primary TCCs were deparaffinised
and rehydrated. Endogenous peroxide was blocked by 3%
hydrogen peroxide for 5 min followed by a wash for 5 min
with PBS. The tissue sections were incubated with the anti-
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Table I The distribution of patients into clinical stage groups and
WHO grades
Clinical stage
Histological grade Ta-TI T2 T3 T4
I 46 10 3 2
II 36 33 12 4
III 8 11 7 6
Total 90 54 22 12
The relation between clinical stage and WHO grade is significant
(X2 = 34.7, P<0.0001).
PCNA/cyclin monoclonal mouse anti-human PCNA (Dako,
code No: M879) diluted at 1:30 in PBS. Several dilutions
were tested to avoid background staining and to find optimal
nuclear staining before the entire series was processed. Sec-
tions were then washed twice 5 min with PBS, incubated for
20 min with horse anti-mouse bionylated secondary antibody
(Vector, CA) diluted at 1:200 in PBS. Slides were washed
twice in PBS for 10 min and incubated for 20 min in per-
formed avidin-biotinylated peroxidase complex (ABC, Vec-
tastain Elite kit, Vector, Ca). Sections were washed twice
5 min with PBS, developed with diaminobenzidine tetra-
hydrochloride substrate (Sigma, UK), slightly counterstained
with Mayer's hematoxylin, dehydrated, cleared and mounted.
Scoring ofPCNA/cyclin positivity
The fraction of positively stained nuclei (all that showed
identifiable positivity) was counted (P.L.) as described pre-
viously (Woods et al., 1991) with some modifications. Firstly
the entire section was screened to find the region with the
maximum number of positively stained nuclei in one micro-
scope field (magnification 60 x, field diameter 490pm). The
fraction of positively stained nuclei in this region was the
PCNAmax (PCNAmax = number of nuclei positive for
PCNA divided by the total number of nuclei). PCNAtot was
the fraction of positively stained nuclei in the entire section.
The estimation of PCNAtot was based on the assessment of
PCNA/cyclin positivity in 5-10 fields (magnification 90 x,
field diameter 490tim) in the areas of subjectively evaluated
regions of average staining. Normal human tonsil was used
as a control and the nuclei in germinal centers always showed
intense positivity for PCNA/cyclin (Figure la). A negative
control was always negative for PCNA/cyclin (normal human
tonsil processed without primary antibody).
Flow cytometry, Ag-NOR method and mitoticfrequency
analysis
The results and method of flow cytometry (Lipponen et al.,
1991c), Ag-NOR technique (Lipponen et al., 1991d) and
mitotic frequency analysis (Lipponen et al., 1990a,b, 1991b)
in the present cohort has been reported previously in the
literature. The reader is referred to original reports for
details.
Statistical analysis
In basic statistical calculations the SPSS/PC+ program
package was used in a Toshiba T3200 computer and the
statistical tests used are indicated in connection with the
results when appropriate. Differences between the means
were tested by analysis of variance (multiple groups) and
t-test (two groups). Frequency distributions were tested by
the chi-square test. Univariate survival analysis was based on
life-table method with statistics (logrank analysis) by Lee and
Desu (1972). Multivariate survival analysis (Cox, 1972) was
done with the BMDP(2L) program package in a stepwise
manner. Several group limits were tested for PCNA/cyclin
positivity. The fraction of 50% of PCNA/cyclin positive
nuclei gave the best prognostic estimates and it is used in the
survival analyses. The group limits for other continuous
variables are based on the results of previous reports (Lip-
ponen et al., 1990b, 1991c, 1991d).
Results
The fraction of nuclei positive for PCNA/cyclin varied
between 0% and 100%. The mean(s.e.) of PCNAmax was
46% (3%) and the mean(s.e.) of PCNAtot was 29% (2%).
PCNA/cyclin immunostaining was almost entirely confined
to the nucleus showing usually a diffuse uniform staining. In
some of the nuclei staining was granular and in occasional
cells the cytoplasm was uniformly positive for PCNA/cyclin.
Tumours with positivity in the cytoplasm were usually WHO
grade 3 tumours. Mitotic cells were negative or only slightly
positive for PCNA/cyclin.
PCNA/cyclin positivity was variable in all WHO grades.
Low grade tumours showed only few positive nuclei whereas
in WHO grade 3 tumours most of the nuclei were positive
for PCNA/cyclin (Table II). In low grade tumours positive
nuclei were located in the basal cell layer of the epithelium
(Figure lb) whereas in WHO grade 2-3 tumours nuclei
positive for PCNA/cyclin were present also in superficial cell
layers (Figure lc). The fraction of nuclei positive for PCNA/
cyclin was regionally variable in some of the tumours (Figure
ld).
Non-papillary tumours had a significantly higher growth
fraction than papillary tumours and the fraction of positive
nuclei was related to T-category (Table II). T1-4N0 tumours
had a significantly (P<0.001) lower growth fraction [mean
(s.e.), 41% (3%), n = 153] then the tumours with lymph node
metastasis [mean(s.e.), 74% (6%), n = 25].
The significant relationship between DNA ploidy, S phase
fraction, AgNOR count, M/V index and PCNA/cyclin posit-
ivity is shown in Table III.
Progression in T-, N- and M-categories was related to
PCNA/cyclin positivity (Table IV). In Ta-TI tumours pro-
gression in T-category (P = 0.1), N-category (P = 0.1) and in
M-category (P = 0.019) was related to the fraction ofPCNA/
cyclin positive nuclei. The mean(s.e.) ofPCNA/cyclin positive
nuclei in tumours which showed progression (n = 13) in M-
category was 41.2 (10.6)% in contrast to 19.4 (3.3)% in
non-progressing tumours (n = 77) (P = 0.019, t =-2.39,
D.F. = 88).
The survival of patients categorised according to all prog-
nostic variables is shown in Table V. The survival ofpatients
categorised according to PCNAtot in the entire cohort and in
Ta-Ti tumours is graphically shown in Figures 2 and 3. The
predictive value of PCNAmax was practically similar to that
of PCNAtot in all analyses and thus survival data related to
PCNAmax is not shown. If the group limit for PCNA/cyclin
positivity was lower or higher than 50% the survival curves
were not so widely separated. The results of multivariate
survival analysis including all the presented variables are
summarised in Table VI. The prognostic value of PCNAmax
and PCNAtot were almost similar albeit in superficial
tumours the PCNAtot was a better predictor.
Discussion
Proliferating cell nuclear antigen is an intranuclear polypep-
tide and it's synthesis reaches the maximum during the S-
phase (Celis & Celis, 1985; Morris & Mathews, 1989).
PCNA/cyclin is an polymerase delta related accessory protein
which is essential for cellular DNA synthesis (Jaskulski et al.,
1988) and preliminary results suggest that increase ofPCNA/
cyclin protein might be related to chemotherapy resistance of
cancer cells (Haneda et al., 1991). At present the entire gene
for human PCNA has been sequenced and isolated (Travali
et al., 1989; Almedral et al., 1987). The immunohistochemical
demonstration of PCNA/cyclin allows the estimation of
growth fraction (Tsujihashi et al., 1991) in human tumours.
The method for detection of PCNA/cyclin is the first method
that allows the estimation of growth fraction in paraffin-
embedded biopsy specimens of TCC and makes it possible to
visualise proliferating cells in context of histopathology. The
results showed that PCNA/cyclin can be reliably demon-
strated in routinely processed formalin fixed paraffin embedd-PCNA/CYCLIN IMMUNOSTAINING IN TRANSITIONAL CELL BLADDER TUMOURS 173
Figure 1 a, Most of the nuclei in a germinal center of a normal tonsil are positive for PCNA/cyclin (magnification 100 x ). b, A
papillary WHO grade 1 TCC with few PCNA/cyclin positive nuclei in the basal cell layer (magnification 100 x ). c, A nodular
WHO grade 3 TCC in which most of the nuclei are positive for PCNA/cyclin (magnification 400 x ). d, The fraction of nuclei
positive for PCNA/cyclin is regionally variable in a papillary WHO grade 2 TCC (magnification 100 x ).
Table II The mean (s.e.) ofPCNAmax and PCNAtot inT-categories,
in WHO grades and in papillary and non-papillary tumours
Subgroup Number PCNAmax pa PCNAtot pa
T-category
Ta 2 5(5) F=2.8 1(1) F=3.5
TI 88 38 (4) D.F=4 23 (3) D.F. =4
T2 54 54 (5) P= 0.027 32 (4) P= 0.008
T3 22 50 (9) 39 (9)
T4 12 66 (10) 55 (10)
Papillary status
t=-5.6 t=-5.4
papillary 149 40 (3) D.F. = 49.7 23 (2) D.F. = 38.1
non-papillary 29 76 (5) P<0.001 60 (6) P<0.001
WHO grade
I 61 24(4) F=24.3 10(2) F=40.2
II 85 50 (4) D.F. = 2 29 (3) D.F. = 2
III 32 77 (6) P<0.001 66 (6) P<0.001
aAnalysis of variance; with papillary status Student's t-test
D.F. = degrees of freedom; F = test value for analysis of variance;
t = test value for t-test.
ed section and the growth fraction can be correlated to other
prognostic variables and survival in TCC.
The staining pattern for PCNA in TCC was similar to that
reported in other human neoplasms (Kamel et al., 1991;
Woods et al., 1991; Yu et al., 1991). Low grade tumours
showed only few nuclei positive for PCNA/cyclin whereas in
high grade tumours most of the nuclei were positive for
PCNA/cyclin which is accordance with the results of Ki-67
immunostaining in TCC (Tsujihashi et al., 1991; Bush et al.,
1991).
PCNA/cyclin positivity was related to papillary status and
T-category so that nodular tumours and muscle invasive
tumours had a higher fraction of PCNA/cyclin positive
nuclei than superficial papillary tumours. The results are in
full agreement with the results of Ki-67 immunolabelling in
TCC (Tsujihashi et al., 1991; Bush et al., 1991). A similar
relationship between papillary status, T-category, Ag-NORs
(Lipponen et al., 1991d), nuclear morphometric variables
(Lipponen et al., 1990b), mitotic indices (Lipponen & Eske-
linen, 1990b), DNA ploidy and S phase fraction (Lipponen et
al., 1991c) has been reported previously in the same cohort of
TCCs. Tumours with pelvic lymph node metastasis had a
higher growth fraction as determined by PCNA/cyclin than
local tumours which is in full agreement with the results from
flow cytometry (Lipponen et al., 1991c; Shaaban et al., 1991),174 P.K. LIPPONEN & M.J. ESKELINEN
Table III The mean (s.e.) of PCNAmax and PCNAtot in relation to DNA ploidy, S
phase fraction, M/V index and Ag-NORs
Subgroup Number PCNAmax pa PCNAtot pa
DNA ploidy
t=-5.9 t=-5.3
Diploid 113 35 (4) D.F. = 106.5 21 (3) D.F. = 82.6
Aneuploid 50 71(5) P<0.001 51(5) P<0.001
SPF
30(4) t=-6.5 t=-7.1
< 10% 99 71 (5) D.F. = 147.0 16 (2) D.F. = 76.4
> 10% 50 P<0.001 56 (5) P<0.001
M/V index
t=-7.4 t=-7.1
< 10mm-2 109 31 (3) D.F.= 176 16 (2) D.F.= 119.3
>10mm-2 69 71 (4) P<0.001 51 (4) P<0.001
Ag-NOR
t=-5.0 t=-5.5
<,3.5 113 35 (3) D.F. =166 19 (3) D.F. =166
>3.5 55 66 (5) P<0.001 48 (4) P<0.001
aStudent's t-test; see abbreviations in Table II.
Table IV Mean (s.e.) values ofPCNAtot in progressing and non-progressing tumours and the
number of progressing and non-progressing tumours subdivided according to PCNAtot value
50%
PCNAtot PCNAtot (%)
Category Number (s.e.) pa 50 >50 pb
T-category
t =-l.9 x2= 4
No progression 125 26 (3) D.F. = 176 95 30 D.F. = 1
Progression 53 37 (5) P= 0.054 33 20 P = 0.0622
N-category
t=-3.7 x2 =8
No progression 127 24 (3) D.F. = 176 99 28 D.F. = 1
Progression 51 44 (5) P<0.001 29 22 P = 0.0046
M-category
t=-4.22 X2 = 13
No progression 125 23 (3) D.F. = 80 100 25 D.F. = 1
Progression 53 47 (5) P<0.001 28 25 P = 0.0002
4Student's t test; bChi square test; see abbreviations in Table II.
Table V The survival ofpatients categorised according to prognostic
variables
Variable Number Survival at V2, D.F., Pa
10 years (%)
Ta 2 100%
TI 88 85%
T2 54 55% 57.4, 4, <0.0001
T3 22 50%
T4 12 0%
Grade I 61 85%
Grade II 85 70% 39.7, 2, <0.0001
Grade III 32 25%
Papillary 149 75%
Non-papillary 29 20% 28.1, 1, <0.0001
M/V < 10mm-2 109 80%
M/V>10mm-2 69 55% 13.4, 1, 0.0002
Diploid 113 75%
Aneuploid 50 55% 5.4, 1, 0.0191
SPF < 10% 99 80%
SPF>10% 50 50% 20.6, 1, <0.0001
AgNORs < 3.5 113 75%
AgNORs>3.5 55 55% 11.0, 1, 0.0009
PCNAtot < 50% 128 85%
PCNAtot>50% 50 45% 28.3, 1, <0.0001
PCNAmax < 50% 95 85%
PCNAmax>50% 83 50% 20.0, 1, <0.0001
aLogrank analysis. M/V= M/V index.
Ag-NOR analysis (Lipponen et al., 1991d), mitotic frequency
analysis (Lipponen et al., 1990a) and Ki-67 immunolabelling
(Tsujihashi et al., 1991; Bush et al., 1991).
Aberrant cytoplasmic positivity for PCNA/cyclin has been
previously described in lymphomas but the biological signi-
ficance of this phenomenon is unknown (Bejamin & Grown,
Table VI The results ofCox's survival analysis in the entire cohort, in
papillary tumours and in Ta-TI tumours
Variable 1 (s-e.) 1 (s.e.) P Hazard rate
All cases
T-category 0.865 (0.153) 5.667 <0.001 2.37 (1.75-3.22)
WHO grade 0.593 (0.250) 2.374 <0.001 1.80 (1.09-2.98)
PCNAmax 0.008 (0.004) 1.938 0.046 1.01 (1.00-1.02)
Papillary tumours
T-category 0.923 (0.204) 4.513 <0.001 2.51 (0.51-3.78)
PCNAmax 0.008 (0.004) 1.732 0.006 1.01 (1.00-1.02)
WHO grade 0.565 (0.329) 1.719 0.088 1.75 (0.91-3.39)
Ta-TI tumours
PCNAtot 0.022 (0.009) 2.519 0.015 1.02 (1.00-1.04)
Only independent predictors (P 0.1) are shown. The P coefficient
describes how each factor contributes to the hazard andP/s.e. describes
theirsignificance(z-value). Thehazard rateforeachfactorwith the95%
confidence interval is given.
1991). Occasional aberrant cytoplasmic staining was observed
in some of the WHO grade 3 tumours which may indicate an
abnormality in transport or metabolism of this protein or a
staining artefact due to leakage of the protein during the
processing of samples. The phenomen was restricted to WHO
grade 3 tumours which might indicate some biological basis
for the PCNA/cyclin expression in the cytoplasm. Most of
the mitotic cells were negative for PCNA/cyclin which con-
curs with the low concentration of this nuclear polypeptide in
M-phase (Celis & Celis, 1985; Morris & Mathews, 1989).
PCNA/cyclin immunostaining was significantly related to
other proliferation indices. Aneuploid tumours with a high
S-phase fraction showed a high fraction of nuclei positive for
PCNA/cyclin which is in agreement with previous reports
from other human neoplasms (Woods et al., 1991). In accor-PCNA/CYCLIN IMMUNOSTAINING IN TRANSITIONAL CELL BLADDER TUMOURS 175
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Figure 2 Survival of patients in the entire cohort categorised
according to fraction of nuclei positive for PCNA/cyclin
(X2=28.3, P<0.0001). Curve A: PCNAtot<50%, n= 128;
Curve B: PCNAtot> 50%, n = 50. The number of patients at
risk are shown at 5 and 10 years.
dance with the above tumours with high mitotic frequency
and large numbers of Ag-NORs were positive for PCNA/
cyclin.
Progression of TCC was related to fraction of nuclei posi-
tive for PCNA/cyclin. However, PCNA/cyclin positivity was
inferior to mitotic frequency or flow cytometric variables
(Lipponen et al., 1990b, 1991c; Carbin et al., 1991) in pre-
dicting progression since we could not establish independent
predictive value for PCNA/cyclin in a multivariate analysis.
Particularly in superficial tumours PCNA/cyclin was inferior
to other proliferation indices in predicting progression (Lip-
ponen et al., 1990b, 1991c).
In univariate survival analysis the fraction of PCNA/cyclin
positive nuclei predicted survival significantly like other
histoquantitative methods (Blomjous et al., 1989; Lipponen
et al., 1990a; 1991a,b; Carbin et al., 1991). The results in
papillary tumours were comparable to those from other
quantitative methods (Lipponen et al., 1991a,b) whereas in
superficial tumours PCNA/cyclin positivity was superior to
morphometric methods in predicting survival. The better
results in superficial tumours may be related to methodo-
logical factors. Biopsy specimens from superficial tumours
are often small which makes the enumeration of mitotic
figures or estimation S-phase fraction difficult. The estima-
tion of growth fraction by PCNA/cyclin immunostaining or
enumeration of Ag-NORs (Lipponen et al., 1991d) can be
estimated on the basis of a relatively small number of nuclei.
The results of Cox's analysis confirm that already estab-
lished prognostic factors (Blomjous et al., 1989; Lipponen et
al., 1991a,b) are more important predictors than PCNA/
cyclin immunostaining in a mixed cohort of TCCs. However,
the results clearly emphasise the importance of cell prolifera-
tion as a determinant of survival in TCC as well as in other
epithelial neoplasms (Aaltomaa et al., 1991; Haapasalo et al.,
1989). The present results particularly show that cell pro-
liferation is important in TI TCCs as shown previously also
by mitotic frequency analyses (Lipponen et al., 1990b). The
identification of new reliable prognostic markers in super-
ficial tumours is important since conventional methods are
often insufficient for prognostic purposes (Zingg & Wallace,
1985). In other local human tumours as well (Aaltomaa et
al., 1991; Haapasalo et al., 1989) cell proliferation is an
important prognostic factor. However, it seems that pro-
liferation rate alone does not determine the survival. Factors
related to cellular differentiation and metastatic potential are
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Figure 3 Survival of patients with a Ta-TI transitional cell
bladder tumour categorised according to fraction of nuclei
positive for PCNA/cyclin (X2 = 11.9, P = 0.0005). Curve A:
PCNAtot < 50%, n = 70; Curve B: PCNAtot > 50%, n = 20.
The number of patients at risk are shown at 5 and 10 years.
important as well (Berger et al., 1987). One should also
realise that this analysis was based on the primary tumour
biopsy specimens. It is well known that the state of the
surrounding epithelium significantly affects on the survival of
patients in TCC (Olsen et al., 1988).
Certain methodological aspects need consideration in this
context, too. The variability of data related to fraction of
PCNA/cyclin positive nuclei in cancers may be due to lack of
sensitivity of detection systems and variations in scoring
processes (Kamel et al., 1991; Collan et al., 1987; Kosma et
al., 1986; Bush et al., 1991). The staining intensity ofnuclei is
highly variable and the inclusion of nuclei with intense stain-
ing only may skew the result towards a smaller growth
fraction than the actual size. Thus in the present analysis, all
the nuclei that showed identifiable positive staining were
included in the scoring process which a method has been
recommended previously (Kamel et al., 1991). Since the posi-
tive staining was regionally variable two quantitation
methods were used, however, they both gave practically simi-
lar results in survival analysis. The growth fraction 50% gave
the best prognostic results in TCC whereas in lymphomas
and hemangiopericytomas substantially lower figures have
been used as group limits (Woods et al., 1991; Yu et al.,
1991). The intraobserver reproducibility was assessed in 20
cases at different times of measurement and the standard
error of the mean of PCNAtot and PCNAmax was
always<5%. The reproducibility of the assessment of Ki-67
immunostaining which gives practically a similar staining
result in TCC has also been high (Bush et al., 1991). In
practice it is too laborious and probably also unnecessary for
prognostic purposes to score the entire section to assess the
fraction of proliferating cells.
In conclusion (a) PCNA/cyclin immunostaining can be
applied in routinely processed paraffin embedded biopsy
specimens to assess the growth fraction in TCC, (b) the
fraction of nuclei positive for PCNA/cyclin correlates signi-
ficantly to established proliferation indices and clinico-
pathological variables in TCC, (c) quantitation of PCNA/
cyclin immunostaining has prognostic value in TCC, (d) the
results encourage for further investigation on the applic-
ability of PCNA/cyclin immunostaining and growth fraction
in general in prediction of prognosis of TCCs.
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